Compare AXTI & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXTI | AMPH |
|---|---|---|
| Founded | 1986 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1998 | 2014 |
| Metric | AXTI | AMPH |
|---|---|---|
| Price | $24.21 | $28.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $11.05 | ★ $31.00 |
| AVG Volume (30 Days) | ★ 7.0M | 313.7K |
| Earning Date | 02-19-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.27 |
| Revenue | $90,390,000.00 | ★ $723,305,000.00 |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $33.52 | $4.84 |
| P/E Ratio | ★ N/A | $12.14 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.13 | $20.39 |
| 52 Week High | $28.65 | $32.69 |
| Indicator | AXTI | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 57.47 | 54.66 |
| Support Level | $23.60 | $27.24 |
| Resistance Level | $28.65 | $29.09 |
| Average True Range (ATR) | 3.25 | 0.83 |
| MACD | 0.43 | 0.06 |
| Stochastic Oscillator | 66.86 | 63.11 |
AXT Inc is a developer and producer of compound and single element semiconductor substrates, also known as wafers. The dominant substrates used in producing semiconductor chips and other electronic circuits are made from silicon. It is engaged in the design, development, manufacture, and distribution of high-performance compound semiconductor substrates and the sale of materials. The company provides alternative or specialty materials in the form of substrates or wafers, including compound and single-element substrates. Its compound substrates combine indium with phosphorous or gallium with arsenic. Geographically firm has its business presence across the region of Europe, Japan, Taiwan, China, North America, and the Asia Pacific from which China derives its maximum revenue to the company.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.